Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1980 1
1982 1
1983 1
1984 1
1985 1
1990 2
1991 2
1993 1
1994 1
1995 1
1996 2
1997 1
1999 1
2000 2
2001 3
2002 2
2003 3
2004 3
2005 3
2006 4
2007 6
2008 4
2009 8
2010 2
2011 3
2012 3
2013 6
2014 11
2015 11
2016 9
2017 15
2018 15
2019 15
2020 12
2021 12
2022 10
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

166 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Gastric Carcinoma"
Page 1
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.
Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K. Doi T, et al. Lancet Oncol. 2017 Nov;18(11):1512-1522. doi: 10.1016/S1470-2045(17)30604-6. Epub 2017 Oct 13. Lancet Oncol. 2017. PMID: 29037983 Clinical Trial.
We assessed its safety and tolerability in patients with advanced breast and gastric or gastro-oesophageal tumours. METHODS: This was an open-label, dose-escalation phase 1 trial done at two study sites in Japan. Eligible patients were at least 20 years old with bre …
We assessed its safety and tolerability in patients with advanced breast and gastric or gastro-oesophageal tumours. METHODS: This was …
Precision medicine for human cancers with Notch signaling dysregulation (Review).
Katoh M, Katoh M. Katoh M, et al. Int J Mol Med. 2020 Feb;45(2):279-297. doi: 10.3892/ijmm.2019.4418. Epub 2019 Dec 4. Int J Mol Med. 2020. PMID: 31894255 Free PMC article. Review.
ADCs and CAR-Ts could alter the therapeutic framework for refractory cancers, especially diffuse-type gastric cancer, ovarian cancer and pancreatic cancer with peritoneal dissemination. Phase III clinical trials of Rova-T for patients with small-cell lung can …
ADCs and CAR-Ts could alter the therapeutic framework for refractory cancers, especially diffuse-type gastric cancer, ovarian …
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT. Kang YK, et al. Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6. Lancet. 2017. PMID: 28993052 Clinical Trial.
BACKGROUND: Patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, two or more previous regimens of chemotherapy have a poor prognosis, and current guidelines do not recommend any specific treatments for these patients. …
BACKGROUND: Patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, two or more …
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ. Moore KN, et al. Lancet Oncol. 2019 May;20(5):636-648. doi: 10.1016/S1470-2045(19)30029-4. Epub 2019 Apr 1. Lancet Oncol. 2019. PMID: 30948273 Clinical Trial.
Patients had received a median of four (IQR 3-5) previous lines of therapy, and the median follow-up for overall survival was 12.2 months (IQR 3.7-22.1). 151 (33%) of 463 patients were resistant and 161 (35%) of 463 patients were refractory to the last administered platinu …
Patients had received a median of four (IQR 3-5) previous lines of therapy, and the median follow-up for overall survival was 12.2 months (I …
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Janjigian YY, Bendell J, Calvo E, Kim JW, Ascierto PA, Sharma P, Ott PA, Peltola K, Jaeger D, Evans J, de Braud F, Chau I, Harbison CT, Dorange C, Tschaika M, Le DT. Janjigian YY, et al. J Clin Oncol. 2018 Oct 1;36(28):2836-2844. doi: 10.1200/JCO.2017.76.6212. Epub 2018 Aug 15. J Clin Oncol. 2018. PMID: 30110194 Free PMC article. Clinical Trial.
Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced gastric or gastroesophageal junction cancers. We assessed the safety and efficacy of nivolumab and nivolumab plus ipilimumab in Western patients with chemotherapy-refrac …
Nivolumab demonstrated superior overall survival (OS) versus placebo in Asian patients with advanced gastric or gastroesophageal junc …
Docetaxel.
Cortes JE, Pazdur R. Cortes JE, et al. J Clin Oncol. 1995 Oct;13(10):2643-55. doi: 10.1200/JCO.1995.13.10.2643. J Clin Oncol. 1995. PMID: 7595719 Review.
PURPOSE: We reviewed the preclinical and clinical profiles of the antineoplastic taxoid docetaxel (Taxotere, Rhone-Poulenc Rorer, Collegeville, PA). ...Responses were observed in breast, bronchial, and ovarian carcinomas. The recommended dose for phase II studies wa …
PURPOSE: We reviewed the preclinical and clinical profiles of the antineoplastic taxoid docetaxel (Taxotere, Rhone-Poulenc Rorer, Col …
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M. Türeci O, et al. Ann Oncol. 2019 Sep 1;30(9):1487-1495. doi: 10.1093/annonc/mdz199. Ann Oncol. 2019. PMID: 31240302 Free PMC article. Clinical Trial.
BACKGROUND: Claudin 18.2 (CLDN18.2) is physiologically confined to gastric mucosa tight junctions; however, upon malignant transformation, perturbations in cell polarity lead to CLDN18.2 epitopes being exposed on the cancer cell surface. ...CONCLUSIONS: Zolbetuximab monoth …
BACKGROUND: Claudin 18.2 (CLDN18.2) is physiologically confined to gastric mucosa tight junctions; however, upon malignant transforma …
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ. Javle M, et al. Oncologist. 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. Oncologist. 2023. PMID: 37390492 Free PMC article. Review.
This review summarizes the preclinical and clinical development of futibatinib, an irreversible FGFR1-4 inhibitor. ...Exploratory analyses indicated clinical benefit with futibatinib after prior FGFR inhibitor use. In a pivotal phase II trial, futibatinib dem …
This review summarizes the preclinical and clinical development of futibatinib, an irreversible FGFR1-4 inhibitor. ...Exploratory ana …
Immunotherapeutic advances in gastric cancer.
Yoneda A, Kuroki T, Eguchi S. Yoneda A, et al. Surg Today. 2021 Nov;51(11):1727-1735. doi: 10.1007/s00595-021-02236-2. Epub 2021 Feb 15. Surg Today. 2021. PMID: 33590326 Review.
Despite the development of combination chemotherapies, the survival rates of patients with gastric cancer remain unsatisfactory. Given the growing evidence of the benefits of immunotherapy as an alternative treatment for other cancers such as advanced melanoma, non-small c …
Despite the development of combination chemotherapies, the survival rates of patients with gastric cancer remain unsatisfactory. Give …
Immunotherapy in esophagogastric cancer.
Ilson DH. Ilson DH. Clin Adv Hematol Oncol. 2021 Oct;19(10):639-647. Clin Adv Hematol Oncol. 2021. PMID: 34637430 Free PMC article. Review.
The uses of immune checkpoint inhibitors have now been advanced to include the first-line treatment of esophagogastric cancers. Initially approved for the treatment of chemotherapy-refractory programmed death ligand 1-positive or microsatellite instability (MSI)-high esoph …
The uses of immune checkpoint inhibitors have now been advanced to include the first-line treatment of esophagogastric cancers. Initially ap …
166 results